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WS3.5 Patients diagnosed with CF in adulthood; clinical course
following diagnosis and treatment at a regional UK centre
C. Etherington1, L. Cassidy1, R. Watson1, S.P. Conway1, D. Peckham1. 1Regional
Adult Cystic Fibrosis Unit, St James’s University Hospital, Leeds, United Kingdom
Introduction: Adult diagnosed patients represent a unique population that differ in
their clinical, genetic and prognostic characteristics compared to those diagnosed
in childhood. With a different spectrum of CFTR mutations, infections and organ
involvement response to standard CF treatments is unknown.
Aims: To determine clinical status at diagnosis and assess response to CF centre
treatment over a 4 yr period.
Methods: All patients diagnosed after 16 yrs of age (2005 to 2011) were included.
Clinical data at diagnosis were collected from electronic patient records (EMIS®).
Best FEV1, weight and BMI for each subsequent 12 month interval recorded.
Results: 20 patients (12 male, 75% PS, median (range) age at diagnosis 30(17−60)
yrs, BMI 21.8(16.7–31.9), FEV1 66(43–101) and FVC 87(62–106)% predicted)
were included. 10 patients were diagnosed due to bronchiectasis and 10 non-
respiratory [infertility (6), family history (3) and malabsorption (1)]. Median BMI
at diagnosis was greater in those with PS vs. PI (22.0 vs. 19.2, p< 0.01). BMI
increased from 21.8 at diagnosis to 24.6 at yr 4. Median weight gain over 4 yrs
was 6.25 kg (5 kg PS vs. 12.3 kg PI, p< 0.005). FEV1 was greater at diagnosis in
those with a non-respiratory diagnosis (93 vs. 60% predicted, p< 0.005). In patients
with bronchiectasis FEV1 increased from 60 to 75% predicted at 1 yr; this increase
was maintained at 4 yrs (78% predicted). No increase in FEV1 in those with a
non-respiratory diagnosis.
Conclusions: Adult diagnosed CF patients do demonstrate signiﬁcant improvements
in both nutritional and respiratory status in response to CF centre treatment and
care, especially those with PI and bronchiectasis.
WS3.6 The CF-ABLE score: a novel clinical prediction tool in cystic
ﬁbrosis
C. McCarthy1, B.D. Dimitrov2, C. Gunaratnam1, N.G. McElvaney1,3. 1Beaumont
Hospital, Dublin, Ireland; 2Royal College of Surgeons in Ireland, Department of
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Ireland
Determining prognosis and predicting outcomes in cystic ﬁbrosis (CF) is a complex
issue and very few clinically applicable models have been created. Our aim was to
identify clinical variables that predict outcome and create a simple prediction rule.
Single-centre consecutive CF patients (n = 49) were studied over the period 2004–
2010. Baseline clinical parameters were gathered and Forced Expiratory Volume in
1 second (FEV1) measurements were analysed longitudinally. The FEV1 decline
showed a “tipping-point” with a cut-off of 52.8%. Poor outcome was deﬁned as
death or transplantation. Using FEV1, Body Mass Index (BMI), Age and Number
of Exacerbations in last 3 months (NoE) the ABLE score was created. The score
was validated in 370 patients from the National CF registry (area under the ROC
curve=82.1% p< 0.001). A practical validation by two blinded independent CF
clinicians was also performed on randomised sub-sample of the patients.
The ABLE score employs clinical parameters that are measured at every clinic visit.
It is scored from 0 to 7 points. If FEV1 is below 52.8% then 3.5 points are added,
1.5 points is added if NoE is more than 1 in 3 months, if BMI is less than 20 or
Age less than 24 then each gets 1 point. There is a linear increased risk of death
or referral to transplant as patients score higher (r≈ 0.80, p< 0.003).
Patients with a low score have almost no chance of death or needing lung
transplantation within 4 years, however as the score increases the risk almost doubles
per point added. Patients in the validation cohort who scored over 5 had a 26.3%
risk of poor outcome within 4 years. This simple score predicts outcome in CF
patients better than FEV1 alone.
WS3.7 Survival at low lung function in cystic ﬁbrosis: cohort study
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M. Osman1, T. Daniels1. 1University Hospital Southampton, Southampton, United
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Background: Outcomes in cystic ﬁbrosis have seen an improvement over the past
20 years but there remains uncertainty on the outcomes of those with severe disease.
An FEV1 of less than 30% predicted has been generally accepted as the cut-off for
consideration for lung transplantation based on a 2 year survival of 50%. Recently
questions have been raised on the signiﬁcance of this threshold.
Aim: To evaluate the survival of patients with CF whose lung function has
deteriorated to an FEV1 below 30% predicted and to explore factors associated
with any change in survival.
Method: Cohort study of CF subjects in the South of England whose FEV1 was
ﬁrst observed to be less than 30% predicted between 1 January 1995 and 31
December 2009. Survival was examined through to 31 December 2010 in four-
year sub-cohorts. At point of entry data was collated on characteristics and current
therapies.
Results: 202 participants in total (111 (55%) male) with median follow up of
5.13 years. Median survival has not been reached for the latest cohort (2004–2009)
but 5 year survival for the ﬁrst cohort (1995–1999) was 37% compared to 64%
for the latest cohort (2004–2009). Use of recombinant DNase was signiﬁcantly
associated with a reduced risk of death (hazard ratio 0.64 95%CI 0.41 to 0.99).
Signiﬁcantly increased risk was associated with BMI <19 (HR 2.19, 1.35 to 3.53)
and long term home oxygen therapy (HR 1.90, 1.15 to 3.94).
Conclusions: The use of FEV1 <30% predicted as the most important indicator for
the timing of lung transplantation is outdated and other factors should be considered.
Survival continues to improve, with the importance of airway clearance treatments
and nutrition reinforced.
WS3.8 The effect of socioeconomic deprivation on clinical outcomes
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Background: Deprivation has an adverse effect on many chronic diseases. Social
class adversely affects life expectancy in CF. We hypothesised that deprivation
would adversely affect clinical outcomes in CF.
Methods: We assessed all 194 children and adolescents with CF under our care in
South and Mid Wales. Height, weight and body mass index standard deviation scores
(SDS) were generated; both FEV1% predicted and slope of change in FEV1% over
3 years were calculated. We assessed 3 measures of socioeconomic deprivation: the
Welsh Index of Multiple Deprivation: Child Index (WIMD) a robust measure which
calculates deprivation within seven domains; Townsend score and Carstairs index.
Relationships between continuous variables were investigated through correlation
and multiple linear regression. WIMD upper and lower quartiles were generated
and compared using un-paired t-test.
Results: Patients with CF lived in signiﬁcantly more deprived locations than
normal − mean WIMD rank 801 v 948 (95%CI diff −225, −68; p< 0.001). However
there was no signiﬁcant relationship between clinical variables and any of the 3
indices of deprivation. Patients living in the WIMD lowest deprivation quartile
were signiﬁcantly taller than those in the highest quartile (mean ht SDS −0.84
v −1.50, 95%CI diff −1.26, −0.06, p = 0.03), but there were no other signiﬁcant
differences.
Conclusions: Our CF population live in signiﬁcantly more deprived communities
than the normal population, but there was little evidence of a deleterious effect
of deprivation on clinically relevant CF outcomes. We speculate that the close
monitoring of CF patients might ameliorate the effects of deprivation.
